| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 98.76% | Wedbush | → $192 | Reiterates | Outperform → Outperform |
| 09/15/2023 | 57.35% | Cantor Fitzgerald | → $152 | Reiterates | Overweight → Overweight |
| 09/07/2023 | 57.35% | Cantor Fitzgerald | → $152 | Reiterates | Overweight → Overweight |
| 09/06/2023 | 38.72% | Wells Fargo | $139 → $134 | Maintains | Overweight |
| 09/06/2023 | 98.76% | Wedbush | $187 → $192 | Maintains | Outperform |
| 09/06/2023 | 16.98% | Morgan Stanley | $109 → $113 | Maintains | Equal-Weight |
| 08/07/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 08/01/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 07/31/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 07/24/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 07/17/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 06/26/2023 | 12.84% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 06/20/2023 | 12.84% | Morgan Stanley | → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 06/14/2023 | -7.87% | Credit Suisse | → $89 | Assumes | → Neutral |
| 06/12/2023 | 12.84% | Morgan Stanley | → $109 | Reiterates | Equal-Weight → Equal-Weight |
| 06/07/2023 | 93.58% | Wedbush | → $187 | Reiterates | Outperform → Outperform |
| 06/02/2023 | 93.58% | Wedbush | $186 → $187 | Maintains | Outperform |
| 06/01/2023 | 57.35% | Cantor Fitzgerald | → $152 | Reiterates | Overweight → Overweight |
| 05/08/2023 | 92.55% | Wedbush | $195 → $186 | Maintains | Outperform |
| 04/28/2023 | 57.35% | Cantor Fitzgerald | $142 → $152 | Maintains | Overweight |
| 04/28/2023 | 12.84% | Morgan Stanley | $107 → $109 | Maintains | Equal-Weight |
| 04/28/2023 | -7.87% | Credit Suisse | $82 → $89 | Maintains | Neutral |
| 04/05/2023 | 51.14% | Citigroup | $163 → $146 | Maintains | Buy |
| 04/05/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 04/04/2023 | 11.8% | Morgan Stanley | $151 → $108 | Downgrades | Overweight → Equal-Weight |
| 04/04/2023 | -4.76% | B of A Securities | $132 → $92 | Maintains | Buy |
| 04/03/2023 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 02/17/2023 | 56.31% | Morgan Stanley | $148 → $151 | Maintains | Overweight |
| 02/17/2023 | 34.58% | Credit Suisse | → $130 | Reiterates | → Outperform |
| 01/17/2023 | 68.74% | SVB Leerink | $148 → $163 | Maintains | Outperform |
| 01/03/2023 | 83.23% | Wells Fargo | $169 → $177 | Maintains | Overweight |
| 11/15/2022 | 53.21% | Morgan Stanley | $146 → $148 | Maintains | Overweight |
| 11/14/2022 | 53.21% | SVB Leerink | $168 → $148 | Maintains | Outperform |
| 11/14/2022 | 69.77% | Wedbush | $151 → $164 | Maintains | Outperform |
| 11/07/2022 | 74.95% | Wells Fargo | $172 → $169 | Maintains | Overweight |
| 11/03/2022 | 34.58% | Credit Suisse | $123 → $130 | Maintains | Outperform |
| 11/03/2022 | 51.14% | Morgan Stanley | $148 → $146 | Maintains | Overweight |
| 11/03/2022 | 68.74% | Citigroup | $157 → $163 | Maintains | Buy |
| 10/20/2022 | 80.12% | Goldman Sachs | → $174 | Initiates Coverage On | → Buy |
| 09/22/2022 | 78.05% | Wells Fargo | $167 → $172 | Maintains | Overweight |
| 08/30/2022 | 71.84% | Berenberg | → $166 | Assumes | → Buy |
| 08/11/2022 | 53.21% | Morgan Stanley | $152 → $148 | Maintains | Overweight |
| 08/11/2022 | 49.07% | Oppenheimer | $154 → $144 | Maintains | Outperform |
| 08/11/2022 | 73.91% | SVB Leerink | $174 → $168 | Maintains | Outperform |
| 05/12/2022 | 27.33% | Credit Suisse | $194 → $123 | Maintains | Outperform |
| 05/12/2022 | 63.56% | Citigroup | $187 → $158 | Maintains | Buy |
| 05/12/2022 | 82.19% | Wells Fargo | $190 → $176 | Maintains | Overweight |
| 05/12/2022 | 80.12% | SVB Leerink | $193 → $174 | Maintains | Outperform |
| 03/15/2022 | 103.93% | Morgan Stanley | $180 → $197 | Maintains | Overweight |
| 03/15/2022 | 66.67% | B of A Securities | $148 → $161 | Upgrades | Neutral → Buy |
| 03/15/2022 | 99.79% | SVB Leerink | $190 → $193 | Maintains | Outperform |
| 03/14/2022 | 100.83% | Credit Suisse | $188 → $194 | Maintains | Outperform |
| 03/07/2022 | 86.34% | Morgan Stanley | $197 → $180 | Maintains | Overweight |
| 03/03/2022 | 21.12% | Wedbush | $128 → $117 | Maintains | Outperform |
| 03/03/2022 | 75.98% | Wells Fargo | $176 → $170 | Maintains | Overweight |
| 03/03/2022 | 94.62% | Credit Suisse | $196 → $188 | Maintains | Outperform |
| 03/01/2022 | 93.58% | Citigroup | → $187 | Initiates Coverage On | → Buy |
| 02/14/2022 | 75.98% | Oppenheimer | → $170 | Upgrades | Perform → Outperform |
| 01/06/2022 | 40.79% | Cowen & Co. | → $136 | Initiates Coverage On | → Market Perform |
| 12/08/2021 | 82.19% | Wells Fargo | → $176 | Initiates Coverage On | → Overweight |
| 11/15/2021 | 96.69% | SVB Leerink | $182 → $190 | Maintains | Outperform |
| 11/11/2021 | 85.3% | Credit Suisse | $185 → $179 | Maintains | Outperform |
| 10/20/2021 | 74.95% | B of A Securities | $164 → $169 | Downgrades | Buy → Neutral |
| 08/26/2021 | 111.18% | Morgan Stanley | $197 → $204 | Maintains | Overweight |
| 08/26/2021 | 91.51% | Credit Suisse | $178 → $185 | Maintains | Outperform |
| 08/26/2021 | 88.41% | SVB Leerink | $178 → $182 | Maintains | Outperform |
| 07/21/2021 | 84.27% | SVB Leerink | $181 → $178 | Maintains | Outperform |
| 06/14/2021 | 95.65% | Wedbush | $219 → $189 | Maintains | Outperform |
| 06/14/2021 | 87.37% | SVB Leerink | $191 → $181 | Maintains | Outperform |
| 06/14/2021 | 103.93% | Morgan Stanley | $201 → $197 | Maintains | Overweight |
| 06/01/2021 | 102.9% | Canaccord Genuity | $190 → $196 | Maintains | Buy |
| 05/28/2021 | 84.27% | Credit Suisse | $176 → $178 | Maintains | Outperform |
| 05/28/2021 | 108.07% | Morgan Stanley | $199 → $201 | Maintains | Overweight |
| 03/30/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/12/2021 | 96.69% | Canaccord Genuity | $172 → $190 | Maintains | Buy |
| 03/11/2021 | 82.19% | Credit Suisse | $178 → $176 | Maintains | Outperform |
| 12/17/2020 | 123.6% | Berenberg | → $216 | Initiates Coverage On | → Buy |
| 11/13/2020 | 106% | Morgan Stanley | $194 → $199 | Maintains | Overweight |
| 11/12/2020 | 84.27% | Credit Suisse | $158 → $178 | Maintains | Outperform |
| 11/12/2020 | 97.72% | SVB Leerink | $173 → $191 | Maintains | Outperform |
| 10/13/2020 | 100.83% | Morgan Stanley | $179 → $194 | Maintains | Overweight |
| 08/31/2020 | 85.3% | Morgan Stanley | $177 → $179 | Maintains | Overweight |
| 08/28/2020 | 63.56% | Credit Suisse | $154 → $158 | Maintains | Outperform |
| 07/15/2020 | 83.23% | Morgan Stanley | $181 → $177 | Maintains | Overweight |
| 05/21/2020 | 87.37% | Morgan Stanley | $180 → $181 | Maintains | Overweight |
| 05/20/2020 | 79.09% | SVB Leerink | $170 → $173 | Maintains | Outperform |
| 05/20/2020 | 59.42% | Credit Suisse | $149 → $154 | Maintains | Outperform |
| 05/20/2020 | 115.32% | Oppenheimer | $219 → $208 | Maintains | Outperform |
| 04/20/2020 | 75.98% | SVB Leerink | $152 → $170 | Maintains | Outperform |
| 04/20/2020 | 54.24% | Credit Suisse | $139 → $149 | Maintains | Outperform |
| 04/20/2020 | 77.02% | Stifel | $146 → $171 | Maintains | Buy |
| 04/20/2020 | 126.71% | Oppenheimer | $199 → $219 | Maintains | Outperform |
| 04/20/2020 | 108.07% | Cantor Fitzgerald | $185 → $201 | Reiterates | → Overweight |
| 04/02/2020 | 86.34% | Morgan Stanley | $181 → $180 | Maintains | Overweight |
| 03/20/2020 | 106% | Oppenheimer | → $199 | Initiates Coverage On | → Outperform |
| 02/26/2020 | 87.37% | Morgan Stanley | $148 → $181 | Maintains | Overweight |
| 01/17/2020 | 53.21% | Morgan Stanley | $140 → $148 | Maintains | Overweight |
| 12/17/2019 | 44.93% | Morgan Stanley | $134 → $140 | Maintains | Overweight |
| 11/20/2019 | 38.72% | Morgan Stanley | $128 → $134 | Maintains | Overweight |
| 10/22/2019 | 92.55% | Wedbush | $191 → $186 | Maintains | Outperform |
| 10/11/2019 | 32.51% | Morgan Stanley | → $128 | Initiates Coverage On | → Overweight |
| 08/29/2019 | 57.35% | JP Morgan | $143 → $152 | Maintains | Overweight |
| 06/03/2019 | 130.85% | Wedbush | $219 → $223 | Maintains | Outperform |
| 05/31/2019 | 49.07% | Canaccord Genuity | $133 → $144 | Maintains | Buy |
| 04/05/2019 | 37.68% | Canaccord Genuity | $132 → $133 | Maintains | Buy |
| 03/29/2019 | 43.89% | Credit Suisse | $151 → $139 | Maintains | Outperform |
| 01/24/2019 | 5.59% | Cantor Fitzgerald | → $102 | Initiates Coverage On | → Overweight |
| 01/24/2019 | -6.83% | Leerink Swann | $73 → $90 | Upgrades | Market Perform → Outperform |
What is the target price for Ascendis Pharma (ASND)?
The latest price target for Ascendis Pharma (NASDAQ: ASND) was reported by Wedbush on November 8, 2023. The analyst firm set a price target for $192.00 expecting ASND to rise to within 12 months (a possible 98.76% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ascendis Pharma (ASND)?
The latest analyst rating for Ascendis Pharma (NASDAQ: ASND) was provided by Wedbush, and Ascendis Pharma reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for Ascendis Pharma (ASND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Ascendis Pharma (ASND) correct?
While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a reiterated with a price target of $0.00 to $192.00. The current price Ascendis Pharma (ASND) is trading at is $96.60, which is within the analyst's predicted range.